Citations

Clear

3942 citation(s) found for "To, Van".

Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12
Keulen, Virginia P. Van , Ciric, B, Radhakrishnan, S. , Heckman, Karin L., Mitsunaga, Yoshihiro, Iijima, Koji, Kita, Hirohito , Rodriguez, Moses , Pease, Larry R. , Ciric, B, Kita, H , Rodriguez, Moses

Mayo Clinic

Clinical and Experimental Immunology | December 20, 2005 | Volume: 143 | Issue: 2 | Pages: 314-321

10.1111/j.1365-2249.2005.02992.x | PMID 16412056 Get It

Summary A patient with Waldenstrom’s macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom’s patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.
Sympathetic Neural Outflow and Chemoreflex Sensitivity Are Related to Spontaneous Breathing Rate in Normal Men
Narkiewicz, Krzysztof , Borne, Philippe van de , Montano, Nicola , Kára, Tomáš, Hering, Dagmara , Somers, Virend K. , Montano, Nicola

Mayo Clinic

Hypertension | December 12, 2005 | Volume: 47 | Issue: 1 | Pages: 51-55

10.1161/01.hyp.0000197613.47649.02 | PMID 16344363 Get It

Respiration contributes importantly to short-term modulation of sympathetic nerve activity. However, the relationship between spontaneous breathing rate, chemoreflex function, and direct measures of sympathetic traffic in healthy humans has not been studied previously. We tested the hypothesis that muscle sympathetic nerve activity and chemoreflex sensitivity are linked independently to respiratory rate in normal subjects. We studied 69 normal male subjects aged 29.6±8.1 years. Subjects were subdivided according to the tertiles of respiratory rate distributions. Mean respiration rate was 10.6 breaths/min in the first tertile, 14.8 breaths/min in the second tertile, and 18.0 breaths/min in the third tertile. Subjects from the third tertile (faster respiratory rate) had greater sympathetic activity than subjects from the first tertile (slower respiratory rate; 29±3 versus 17±2 bursts/min; P <0.001). Stepwise multiple linear regression analysis revealed that only respiratory rate was linked independently to sympathetic activity ( r =0.42; P <0.001). In comparison to subjects with slow respiratory rate, subjects with fast respiratory rate had greater increases in minute ventilation during both hypercapnia (7.3±0.8 versus 3.2±1.0 L/min; P =0.005) and hypoxia (5.7±0.8 versus 2.4±0.7 L/min; P =0.007). Muscle sympathetic nerve activity and chemoreflex sensitivity are linked to spontaneous respiratory rate in normal humans. Faster respiratory rate is associated with higher levels of sympathetic traffic and potentiated responses to hypoxia and hypercapnia. Spontaneous breathing frequency, central sympathetic outflow, and chemoreflex sensitivity exhibit significant and hitherto unrecognized interactions in the modulation of neural circulatory control.
SERCA Pump Inhibitors Do Not Correct Biosynthetic Arrest of ΔF508 CFTR in Cystic Fibrosis
Grubb, Barbara R. , Gabriel, Sherif E., Mengos, April, Gentzsch, Martina , Randell, Scott H. , Heeckeren, Anna M. van, Knowles, Michael R. , Drumm, Mitchell L. , Riordan, John R., Boucher, Richard C. , Boucher, Richard C

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | November 11, 2005 | Volume: 34 | Issue: 3 | Pages: 355-363

10.1165/rcmb.2005-0286oc | PMID 16284361 Get It

Abstract Deletion of phenylalanine 508 (ΔF508) accounts for nearly 70% of all mutations that occur in the cystic fibrosis transmembrane conductance regulator (CFTR). The ΔF508 mutation is a class II processing mutation that results in very little or no mature CFTR protein reaching the apical membrane and thus no cAMP-mediated Cl− conductance. Therapeutic strategies have been developed to enhance processing of the defective ΔF508 CFTR molecule so that a functional cAMP-regulated Cl− channel targets to the apical membrane. Sarcoplasmic/endoplasmic reticulum calcium (SERCA) inhibitors, curcumin and thapsigargin, have been reported to effectively correct the CF ion transport defects observed in the ΔF508 CF mice. We investigated the effect of these compounds in human airway epithelial cells to determine if they could induce ΔF508 CFTR maturation, and Cl− secretion. We also used Baby Hamster Kidney cells, heterologously expressing ΔF508 CFTR, to determine if SERCA inhibitors could interfere with the interaction between calnexin and CFTR and thereby correct the ΔF508 CFTR misfolding defect. Finally, at the whole animal level, we tested the ability of curcumin and thapsigargin to (1) induce Cl− secretion and reduce hyperabsorption of Na+ in the nasal epithelia of the ΔF508 mouse in vivo, and (2) induce Cl− secretion in intestine (jejunum and distal colon) and the gallbladder of the ΔF508 CF mouse. We conclude that curcumin and thapsigargin failed to induce maturation of ΔF508 CFTR, or induce Cl− secretion, as measured by biochemical and electrophysiologic techniques in a variety of model systems ranging from cultured cells to in vivo studies.
Hearing loss simulation: A comparison of two methods
Fabry, David A., Tasell, Dianne J. Van

Mayo Clinic

The Journal of the Acoustical Society of America | October 7, 2005 | Volume: 76 | Issue: S1 | Pages: S61-S61

10.1121/1.2021941 Get It

Hearing threshold configuration of the impaired ear was simulated, via two different methods, in the normal ear of each of six subjects with unilateral sensorineural hearing loss. The simulation methods were (1) frequency-specific attenuation (filtering), and (2) masking by shaped masking noise. Identification responses to 20 consonant-vowel nonsense syllables were obtained from the normal ear of each subject in both hearing loss simulation conditions, as well as from the impaired ear. Data were scored both for percent correct syllable recognition and for errors on a set of eight consonant features. Overall performance level and consonant feature error patterns appeared to be relatively independent measures of speech recognition. For three subjects, both masking and filtering successfully simulated the effects of sensorineural hearing loss on consonant feature error patterns. For the remaining subjects, one or both of the simulation schemes was inadequate. [Supported by NINCDS Grant NS-12125.]
The Role of Defective Mismatch Repair in Small Bowel Adenocarcinoma in Celiac Disease
Potter, D. Dean , Murray, Joseph A. , Donohue, John H., Burgart, Lawrence J., Nagorney, David M. , Heerden, Jon A. van, Plevak, Matthew F., Zinsmeister, Alan R., Thibodeau, Stephen N. , Murray, J A

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 19 | Pages: 7073-7077

10.1158/0008-5472.can-04-1096 | PMID 15466202 Get It

Abstract Celiac disease is associated with an increased risk of small bowel adenocarcinoma. The aims of this study were to investigate the molecular basis, assess outcomes, and identify clinicopathologic characteristics of small bowel adenocarcinoma in celiac disease. Retrospective case control cohort study of all celiac disease patients treated at our institution for small bowel adenocarcinoma and matched control patients with sporadic small bowel adenocarcinoma from July 1960 to November 2002. Mismatch repair (MMR) status was accessed by testing tissue for microsatellite instability (MSI) and for hMLH1 and hMSH2 protein expression. Over a 40-year time period, 18 patients with small bowel adenocarcinoma and celiac disease were treated at the Mayo Clinic. One celiac disease patient was excluded. High-frequency MSI (MSI-H) was identified in 8 of 11 (73%) and 2 of 22 (9%) available small bowel adenocarcinoma specimens in the celiac disease and control groups, respectively. In the celiac disease group, MSI-H was associated with loss of hMLH1 and hMSH2 in 6 and 1 specimens, respectively. Loss of hMLH1 occurred in both control tumors. Stage was associated with celiac disease status (P = 0.018), and 78% of controls were stage III or IV compared with 47% of celiac disease patients. Overall, survival was better (P = 0.025) in the celiac disease group compared with stage-matched controls. Celiac disease patients with small bowel adenocarcinoma had a high incidence defective MMR (73%) compared with controls and had better survival compared with stage-matched controls. In addition, celiac disease patients presented more frequently with early-stage small bowel adenocarcinoma. The better survival and earlier presentation of small bowel adenocarcinoma in celiac disease appears to be biologically associated with defective MMR.
Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity
Radhakrishnan, Suresh , Nguyen, Loc T. , Ćirić, Bogoljub , Flies, Dallas B. , Keulen, Virginia P. Van , Tamada, Koji , Rodriguez, Moses , Pease, Larry R. , Chen, Lieping , Rodriguez, Moses

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 14 | Pages: 4965-4972

10.1158/0008-5472.can-03-3025 | PMID 15256470 Get It

Abstract A naturally occurring human antibody potentiates dendritic cell function on cross-linking B7-DC (PD-L2), supporting robust T-cell responses in vitro. Moreover, treatment of dendritic cells with B7-DC cross-linking antibody resulted in secretion of interleukin-12, suggesting a TH1 polarization of this response. Here we show an in vivo immunotherapeutic effect of this B7-DC cross-linking antibody using a poorly immunogenic B16 melanoma tumor model. Treatment of mice systemically with antibody at the time of tumor cell engraftment prevented tumor growth in a CD4 and CD8 T-cell-dependent manner. The protective effect of B7-DC cross-linking antibody treatment was independent of endogenous antibody responses. Tumor-specific CTL precursors could be isolated from lymph nodes draining the tumor site in animals treated with B7-DC cross-linking antibody, but not from those treated with isotype control antibodies. The elicited antitumor responses in vivo were specific and long-lasting. More strikingly, treatment of mice with B7-DC cross-linking antibody after the tumors were established in the lungs resulted in protection in a CD8-, perforin-, and granzyme B-dependent fashion. Depletion of natural killer cells did not block the effects of treatment with B7-DC cross-linking antibody. Together, these findings demonstrate that cross-linking B7-DC with the human IgM antibody sHIgM12 can induce a protective immune response against a weakly antigenic experimental tumor and therefore has potential as a novel immunotherapeutic approach for treating cancer.
Fruits and Vegetables and Ovarian Cancer Risk in a Pooled Analysis of 12 Cohort Studies
Koushik, Anita , Anderson, Kristin E. , Arslan, Alan A. , Brandt, Piet A. van den , Buring, Julie E. , Cerhan, James R. , Colditz, Graham A. , Fraser, Gary E. , Freudenheim, Jo L. , Goldbohm, R. Alexandra, Hankinson, Susan E. , Koenig, Karen L. , Larsson, Susanna C. , Leitzmann, Michael F. , McCullough, Marjorie L. , Miller, Anthony B. , Patel, Alpa V. , Rohan, Thomas E. , Schatzkin, Arthur, Smit, Ellen, Zhang, Shumin M., Smith‐Warner, Stephanie A. , Hunter, David J. , Spiegelman, Donna , Beeson, W. Lawrence , Genkinger, Jeanine M. , Hankinson, Susan E. , Willett, Walter C. , Wolk, Alicja , Cerhan, James R , Koushik, Anita , Arslan, Alan A , Colditz, Graham A , Larsson, Susanna C , McCullough, Marjorie L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 9 | Pages: 2160-2167

10.1158/1055-9965.epi-05-0218 | PMID 16172226 Get It

AbstractBecause fruits and vegetables are rich in bioactive compounds with potential cancer-preventive actions, increased consumption may reduce the risk of ovarian cancer. Evidence on the association between fruit and vegetable intake and ovarian cancer risk has not been consistent. We analyzed and pooled the primary data from 12 prospective studies in North America and Europe. Fruit and vegetable intake was measured at baseline in each study using a validated food-frequency questionnaire. To summarize the association between fruit and vegetable intake and ovarian cancer, study-specific relative risks (RR) were estimated using the Cox proportional hazards model, and then combined using a random-effects model. Among 560,441 women, 2,130 cases of invasive epithelial ovarian cancer occurred during a maximum follow-up of 7 to 22 years across studies. Total fruit intake was not associated with ovarian cancer risk—the pooled multivariate RR for the highest versus the lowest quartile of intake was 1.06 [95% confidence interval (95% CI), 0.92-1.21; P value, test for trend = 0.73; P value, test for between-studies heterogeneity = 0.74]. Similarly, results for total vegetable intake indicated no significant association (pooled multivariate RR, 0.90; 95% CI, 0.78-1.04, for the highest versus the lowest quartile; P value, test for trend = 0.06; P value, test for between-studies heterogeneity = 0.31). Intakes of botanically defined fruit and vegetable groups and individual fruits and vegetables were also not associated with ovarian cancer risk. Associations for total fruits and vegetables were similar for different histologic types. These results suggest that fruit and vegetable consumption in adulthood has no important association with the risk of ovarian cancer.
[O1‐04‐04]: Operational criteria for patient recruitment in trials of mild cognitive impairment
Petersen, Ronald , Thomas, Ronald G. , Grundman, Michael, Pfeiffer, Eric, Sano, Mary , Dyck, Christopher H. van , Thal, Leon J., Bennett, David A. , Kaye, Jeffrey , Levey, Allan I.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.303 Get It

Invited commentary
Heerden, Jon A. van

Mayo Clinic

World Journal of Surgery | August 13, 2005 | Volume: 16 | Issue: 4 | Pages: 758-758

10.1007/bf02067378 Get It

Non‐Hodgkin's lymphoma of the thyroid: Is more than biopsy necessary?
Pyke, Christopher , Grant, Clive S., Kurtin, Paul J. , Heerden, Jon A. van, Bergstralh, Erik J., Habermann, Thomas M. , Kunselman, Allen R. , Hay, Ian

Mayo Clinic

World Journal of Surgery | August 13, 2005 | Volume: 16 | Issue: 4 | Pages: 604-609

10.1007/bf02067333 | PMID 1413831 Get It

AbstractWhereas excisional surgery and radiotherapy have resulted in a favorable outcome when non‐Hodgkin's lymphoma of the thyroid (NHLT) is confined to the thyroid gland, controversy persists over the potential advantage of aggressive debulking in favor of diagnostic biopsy alone when disease cannot be completely resected. Our aims in this study were to delineate the present role of surgery in NHLT in pre‐operative staging, the impact of the extent of resection on achieving complete remission and cause‐specific survival, and patterns of failure. All 62 patients who underwent primary surgery for NHLT at the Mayo Clinic between 1965 and 1989 were analyzed. By postoperative staging, 50 patients were stage IE or IIE. Overall survival was 53% and 46% at 5 and 10 years; 80% for stage IE confined to the thyroid, 58% for stage IE‐extrathyroid, 50% for stage IIE, and 36% for stages IIIE and IVE. Complete remission was achieved in 88% of patients who underwent diagnostic biopsy plus adjuvant therapy alone compared to 85% for patients in whom debulking plus adjuvant therapy was used. There was no difference in cause‐specific survival in these two groups or in cause‐specific survival in two subgroups who achieved complete remission. Relapse after complete remission occurred in 12 (26%) of 46 patients, only 2 of whom survived long‐term after salvage therapy. The role of surgery in NHLT is diminishing and advances that will increase complete remission and relapse‐free survival will not likely involve more aggressive surgical resections.